Review studies that examined the efficacy and safety of Xultophy® 100/3.6, a combination of insulin degludec and liraglutide. The links below will take you to the abstracts of these clinical trials on PubMed.gov, the website of the US National Library of Medicine and National Institutes of Health.
Xultophy® 100/3.6 clinical studies
Lingvay I, Manghi FP, García-Hernández P, et al; for the DUAL V Investigators. JAMA. 2016;315(9):898-907.
Buse JB, Vilsbøll T, Thurman J, et al; on behalf of the NN9068-3912 (DUAL-II) Trial Investigators. Diabetes Care. 2014;37(11):2926-2933.
Linjawi S, Bode BW, Chaykin LB, et al. Diabetes Ther. 2017;8:101-114.